Re: National Coverage Analysis (NCA) for Beta Amyloid Positron Emission Tomography in Dementia and Neurodegenerative Disease (CAG-00431N)
<p>
BIO appreciates this opportunity to comment on Section 220.6 of the National Coverage Determination (NCD) Manual, which addresses coverage for Positron Emission Tomography (PET) scans. Specifically, our comments express support for Medicare coverage of beta-amyloid PET imaging, an innovative and promising technology used in the early detection and treatment of Alzheimer's disease (AD) or cognitive impairment.</p>
Dear Dr. Conway:
The Biotechnology Industry Organization (BIO) appreciates this opportunity to comment on Section 220.6 of the National Coverage Determination (NCD) Manual, which addresses coverage for Positron Emission Tomography (PET) scans. Specifically, our comments express support for Medicare coverage of beta-amyloid PET imaging, an innovative and promising technology used in the early detection and treatment of Alzheimer's disease (AD) or cognitive impairment.
BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products.